Upload
dinhdan
View
223
Download
2
Embed Size (px)
Citation preview
Skin tumors
Dr Hideghéty Katalin PhD
Clinic of Oncotherapy, Univ. Szeged
Epidermal tumors
In situ cc. : Morbus Bowen, M Queyrat
Basal cell carcinoma
Squamosus cell carcinoma
Bőrfüggelék malignómák:
Szőrtüszőből, faggyú és verejtékmirigyekből kiinduló karcinómák
Merkel cell carcinoma
Lymphomas: T cell cutan lymphoma, Mycosis fungoides
Melanoma malignum
Secundaer tumors: Cutaneous, subcutaneous metastases
Skin tumors
BIOPSY-
HISTOLOGY!
Aetiology• Genetic factors: Xeroderma pigmentosum, neurofibroma (may transform to
neurofibrosarcoma)
• Enviromental factors:
– Ultraviolet light (especially in those with fair skin.)
– Tar, arsenic, mineral oils.
• X-ray: diagnostic or therapeutic.
• Long standing scars, fistulas, sinuses.
• Viruses: Burkitt lymphoma ----------- EB
– HPV
– Kaposi sarcoma ( herpes simplex virus- 8)
• Drugs: long lasting use of immunosuppressant like azathioprime,
cyclophosphamide, cyclosporine or even steroids.
Premalignant skin diseases:
• Actinic or solar
keratosis- Actinic
cheilitis
• Bowen's disease
• Chronic scars: burn,
lupus vulgaris, DLE
• Dysplastic nevi and
large congenital nevus
Actinic keratoses
10% risk of malignant transformation
Hypertrophic AK’s
• Liquid nitrogen cryotherapy
• Topical therapies
– 5-FU (Efudex)
– Imiquimod (Aldara)
• Curettage for hypertrophic lesions
Treatment of AK’s
Intraepithelial cc.
• Bowen disease
• Erythroplasia Queyrat
• Breast and vulvar Paget disease
Erythroplasia Queyrat
Morbus Bowen treated with Photo-
Dynamic Therapy (PDT)
Brown, The Lancet Oncology, 2004
Paget disease
Rare intraepidermal adenocarcinoma
It can mimic inflammatory or infectious status
Paget disease of the breast associated frequently
with breast cancer (in 50% palpable cc.)
Biopsy-histology!
PAGET DISEASE
Dysplastic nevi
•Precursors for melanoma
•Markers for melanoma
Lentigo maligna melanoma
• Non-melanoma skin cancers (NMSC)
– Basal cell carcinoma
– Squamous cell carcinoma
– Keratoacanthoma
Risk factors for development of BCC and SCC
• Fair skin (Fitzpatrick’s types I-III)– Blue eyes
– Red hair
• Family history– Genetic syndromes
• Chronic sun exposure
• Old age
• Arsenic, tar
Basal cell carcinoma
BCC- clinical types
• Nodular
– Pigmented
– Infiltrative
• Superficial
• Morpheaform
Nodular BCC
• Chronic lesion
• Easy bleeding
• Pearly border
• Surface telangiectasias
• Head and neck, trunk,
and extremities
Pigmented BCC
• Similar to nodular but with
black discoloration
– Melanin deposits
• Pigmented races
• Face, trunk, and scalp
Superficial BCC
• Erythematous scaly plaque
• Slow growth
• Asymptomatic
• Trunk, extremities, face
Morpheaform BCC
• Resembles scar
• Asymptomatic and slow
growing
• Ill-defined margins
• Marked subclinical
extension
• BCC is the most frequent skin cancer (80%)
– BCC is 4x more frequent than SCC
• Metastases are rare (<1% of cases)
Local destruction of tissue
Treatment of BCC
• Curettage electrodessication (ED/C)
• Surgical excision• Traditional
• Mohs surgery
• Radiation therapy
• Topical therapy– imiquimod
Curable in
>95%
important
the longterm
cosmetic,
funcional
result
High risk areas
Swanson
Radiation therapy
Only in 8-10 %
convencional fractionation wherever possible
3D planning, use of modern treatment technique
Interdisciplinary decision
Dermato-oncology team
Radiation oncologist
Surgeon
Dermato-oncologist
Pathologist
Radiologist/expert
in nuclear medicine
Dermatologists
PATIENT
Basalioma treatment
Radiotherapy PDT treatment
Radiotherapy PDT treatment
Radiotherapy PDT treatment
Radiotherapy PDT treatment
Keratoacanthoma
• Low grade SCC
• Rapid growth over
weeks
• Trauma, sun exposure,
HPV 11 and 16
• May progress to
invasive SCC
Invasive SCC
• Erythematous nodule
• Indurated lesion
• Sun-exposed skin
– Men > women
• Slow growth
Invasive SCC
Treatment of SCC
The prognosis is generally good.
The type of treatment depends on the site, size of the lesion and the
age , general health and cosmetic appearance of the patient.
• Excision of the lesion is the treatment of choice in patients under 60.
– Curettage and cautery
– Cryotherapy for small lesions.
• Radiotherapy when surgery is contraindicated in elderly or diseased
patient or when the surgery is very difficult e.g. near the eye.
Large > 15 mm tumors/at the high risk areas
>20 mm at other areas
Locally advanced, deep infiltrating, unfavourable
localised from cosmetic or functional aspect
recurrent tumors
age > 55 years
Indication of RT
Cutaneous lymphomas
T cell lymphoma
- patch
- plaque
- tumor stage
B cell lymphoma – secundaer manifestations
Cutaneous T-cell Lymphoma(Mycosis fungoides)
• 1. premycotic patch stage
poikiloderma
• Plaque stage
Tumor stage
Malignant Melanoma (MM)
Risk factors- MM
• Fair skin, red hair, and blue eyes
• Intermittent sun exposure
– Sunburns
– Tanning beds
• Freckles and melanocytic nevi
• Family history of melanoma
Clinical types- MM
Superficial spreading melanomaLentigo maligna melanoma
Acral lentiginous melanoma Nodular melanoma
ABCD of Melanoma
• Asymmetry
• Border irregularity
• Color variegation
• Diameter >6mm
Prognostic features- MM
• Good prognosis
– Breslow < 1mm
• Intermediate prognosis
– Breslow 1-4mm
• Bad prognosis
– Breslow >4mm
Treatment of MM
• Surgical excision
– In situ = 5 mm margin
– Invasive= 1-3 cm depending on Breslow’s depth
Sentinel lymph node biopsy- MM
• Recommended for MM with Breslow 1-4mm
– Lymphadenectomy for positive nodes
• Powerful prognostic feature for disseminated disease
Adjuvant Radiation Therapy
in N+ dissected lymphnode region in the case
of capsule invasion or >3+lgl
3DCRT
Dose: 50 + 10 Gy
Adjuvant Chemotherapy
– response 25%, durable control 1%
– no survival advantage demonstrated
– single agent dacarbazine (DTIC)
– multiple combinations carmustine, cisplatin,
DTIC, tamoxifen
Adjuvant Immunotherapy
Interferon
>4mm or N+
high dose IFN-alpha-2b, improved disease-free
and overall survival approx. 1 year
26% dropout rate toxicity
Lentigo maligna 5 yr cure 80% (disfiguring, debilitating
location)
Residual, recurrent, unresectable
In transit metastasis
Palliation: circumscribed manifestation
- lymphnode mets
- bone mets
- brain mets
Radiotherapy of Melanoma
Melanoma malignum
FDG-PET positive tumor outside the norm. CT volume N=6
MM
• Incidence and deaths on rise
• Survival rates increasing due to detection and thorough
treatment
• Depth and nodal status most important prognostic
indicators
• SLD useful
• Adjuvant systemic and RT defined
• Novel agents for metastatic disease
Ipilimumab is a monoclonal anti-
body that targets cytotoxic T lym-
phocyte associated antigen 4
(CTLA-4).
This marker is associated with
promoting a regulatory response by
the immune system, slowing it
down.
By knocking it out, ipilimumab
may shift the body’s immune
response from inaction into action.
Mutated in 60-70% of melanoma
90% of mutations are V600E
Davies et al. Nature 2002; 417:949-54 & Wan PT et al. Cell. 2004 19;116(6):855-67
B-RAF, An Oncogene in 7% of
Human Cancers
Response Rates & B-RAF
Mutation Status
combination chemotherapy
response rate
Wild type B-RAF 33%
Mutant B-RAF 11%
Chang et al. J Transl Med. 2004 Dec 21;2(1):46.
NRASB-RAF
MEK
ERK
MAP kinase pathway
inhibitors in melanoma
PD0325901
ARRY-142886
BAY 43-9006/sorafenib
CHR-265 PLX4032
SB-590885
Cutanious soft tissue sarcomas
Dermatofibrosarcoma protuberans
Sarcoma Kaposi
Malignus fibrosus histiocytoma, fibrosarcoma, haemangiopericytoma,
angiosarcoma, liposarcoma, neurofibroma
Sarcoma Kaposi
Radiosensitive disease
Dose: (12-15x2 Gy)